ARS Pharmaceuticals, Inc. Financing Cash Flow
ARS Pharmaceuticals, Inc. (SPRY) reported Financing Cash Flow of $3.36 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-13
- ARS Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $3.20M, a 18.54% increase year-over-year.
- ARS Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $159.00K, a 78.07% decline year-over-year.
- ARS Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $1.13M, a 98.41% decline year-over-year.
- ARS Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $100.05M, a 14612.50% increase year-over-year.
- ARS Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $104.60M, a 44.47% increase from fiscal 2024.
- ARS Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $72.40M, a 949.41% increase from fiscal 2023.
- ARS Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $6.90M, a 96.38% decline from fiscal 2022.
- ARS Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $190.73M, a 258.80% increase from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 3 month as first filed | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 6 month as first filed | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 9 month as first filed | Net Cash Provided by (Used in) Financing Activities 12 month | Net Cash Provided by (Used in) Financing Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $3.36M 10-Q · filed 2026-08-13 | $4.49M derived: sum of 3 quarters · filed 2026-08-13 | $104.53M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $159.00K 10-Q · filed 2026-05-15 | $1.29M derived: sum of 2 quarters · filed 2026-05-15 | $101.33M derived: sum of 3 quarters · filed 2026-05-15 | $104.03M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $1.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $101.18M derived: sum of 2 quarters · filed 2026-03-09 | $103.87M derived: sum of 3 quarters · filed 2026-08-13 | $104.60M 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | $100.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $102.74M derived: sum of 2 quarters · filed 2026-08-13 | $103.47M 10-Q · filed 2025-11-10 | $174.38M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $2.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $3.42M 10-Q · filed 2026-08-13 | $74.34M derived: sum of 3 quarters · filed 2026-08-13 | $75.02M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $725.00K 10-Q · filed 2026-05-15 | $71.64M derived: sum of 2 quarters · filed 2026-05-15 | $72.32M derived: sum of 3 quarters · filed 2026-05-15 | $72.87M derived: sum of 4 quarters · filed 2026-05-15 | ||||
| 2024-12-31 | $70.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $71.60M derived: sum of 2 quarters · filed 2026-03-09 | $72.14M derived: sum of 3 quarters · filed 2026-03-09 | $72.40M 10-K · filed 2026-03-09 | ||||
| 2024-09-30 | $680.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $1.23M derived: sum of 2 quarters · filed 2025-11-10 | $1.48M 10-Q · filed 2025-11-10 | $3.29M derived: sum of 4 quarters · filed 2025-11-10 | ||||
| 2024-06-30 | $545.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $803.00K 10-Q · filed 2025-08-13 | $2.61M derived: sum of 3 quarters · filed 2025-08-13 | $3.53M derived: sum of 4 quarters · filed 2025-08-13 | ||||
| 2024-03-31 | $258.00K 10-Q · filed 2025-05-14 | $2.06M derived: sum of 2 quarters · filed 2025-05-14 | $2.98M derived: sum of 3 quarters · filed 2025-05-14 | $5.84M derived: sum of 4 quarters · filed 2025-05-14 | ||||
| 2023-12-31 | $1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $2.73M derived: sum of 2 quarters · filed 2025-03-20 | $5.58M derived: sum of 3 quarters · filed 2025-03-20 | $6.90M 10-K · filed 2025-03-20 | ||||
| 2023-09-30 | $921.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $3.77M derived: sum of 2 quarters · filed 2024-11-13 | $5.09M 10-Q · filed 2024-11-13 | $198.91M derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | $2.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $4.17M 10-Q · filed 2024-08-06 | $197.99M derived: sum of 3 quarters · filed 2024-08-06 | $196.44M derived: sum of 4 quarters · filed 2024-08-06 | ||||
| 2023-03-31 | $1.32M 10-Q · filed 2024-05-09 | $195.14M derived: sum of 2 quarters · filed 2024-05-09 | $193.58M derived: sum of 3 quarters · filed 2024-05-09 | $192.96M derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | $193.82M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $192.26M derived: sum of 2 quarters · filed 2024-03-21 | $191.64M derived: sum of 3 quarters · filed 2024-03-21 | $190.73M 10-K · filed 2024-03-21 | ||||
| 2022-09-30 | -$1.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$2.18M derived: sum of 2 quarters · filed 2023-11-09 | -$3.09M 10-Q · filed 2023-11-09 | $1.34M 10-Q · filed 2022-11-02 | $49.73M derived: sum of 4 quarters · filed 2023-11-09 | |||
| 2022-06-30 | -$623.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$1.53M 10-Q · filed 2023-08-10 | $158.00K 10-Q · filed 2022-08-11 | $51.29M derived: sum of 3 quarters · filed 2023-08-10 | $51.44M derived: sum of 4 quarters · filed 2023-08-10 | |||
| 2022-03-31 | -$908.00K 10-Q · filed 2023-05-15 | $19.00K 10-Q · filed 2022-05-12 | $51.91M derived: sum of 2 quarters · filed 2023-05-15 | $52.06M derived: sum of 3 quarters · filed 2023-05-15 | $52.38M derived: sum of 4 quarters · filed 2023-05-15 | |||
| 2021-12-31 | $52.82M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $52.97M derived: sum of 2 quarters · filed 2023-03-23 | $53.29M derived: sum of 3 quarters · filed 2023-03-23 | $53.16M 10-K · filed 2023-03-23 | $614.00K 10-K · filed 2022-03-31 | |||
| 2021-09-30 | $148.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $467.00K derived: sum of 2 quarters · filed 2022-11-02 | $339.00K 10-Q · filed 2022-11-02 | $255.73M derived: sum of 4 quarters · filed 2022-11-02 | ||||
| 2021-06-30 | $319.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $191.00K 10-Q · filed 2022-08-11 | $255.59M derived: sum of 3 quarters · filed 2022-08-11 | $375.45M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | -$128.00K 10-Q · filed 2022-05-12 | $255.27M derived: sum of 2 quarters · filed 2022-05-12 | $375.13M derived: sum of 3 quarters · filed 2022-05-12 | $387.06M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $255.40M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $375.26M derived: sum of 2 quarters · filed 2022-03-31 | $387.19M derived: sum of 3 quarters · filed 2022-03-31 | $408.51M 10-K · filed 2022-03-31 | ||||
| 2020-09-30 | $119.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $131.80M derived: sum of 2 quarters · filed 2021-11-10 | $153.11M 10-Q · filed 2021-11-10 | |||||
| 2020-06-30 | $11.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $33.25M 10-Q · filed 2021-08-12 | ||||||
| 2020-03-31 | $21.32M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |